Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO)
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO)
Trial Category:
Melanoma
Phase
II
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
